



# Prevalence of *Staphylococcus aureus* in External Ocular Infection and the Occurrence of MRSA in Isolates

Essam Yahya A Alshamahi<sup>1</sup>, Huda Zaid Ali AlShami<sup>2</sup> and Hassan A Al-Shamahy<sup>3\*</sup>

<sup>1</sup>Ophthalmology Department, Sana'a University, Yemen

<sup>2</sup>Clinical Immunology Department, Sana'a University, Yemen

<sup>3</sup>Clinical Immunology Department, Sana'a University, Yemen

**\*Corresponding author:** Hassan A. Al-Shamahy, Faculty of Medicine and Health Sciences, Sana'a University, P.O. Box 775 Sana'a, Yemen, Tel: +967-1-239551; Email: shmahe@yemen.net.ye

**Received Date:** June 15, 2020; **Published Date:** July 24, 2020

## Abstract

**Background and aims:** *Staphylococcus aureus* is an opportunist that causes ocular infection and systemic infections in the human body. This organism increases its resistance to many types of antibiotics every day and becomes more resistant, and this led to a growing concern in this era. Given this fact, the aims of this study were to determine the frequency of *S. aureus* in external ocular infections and to determine the prevalence of MRSA strains and the sensitivity of isolated *S. aureus* to antibiotics, in patients who attended selected ophthalmology clinics in major public hospitals and private clinics in the city of Sana'a - Yemen.

**Subjects and methods:** The study was conducted for a year, starting in September 2016 to October 2017, where a total of 197 patients with external eye infections were included in the study. Samples were collected and transferred to the National Center of Public Laboratories (NCPHL), in Sana'a. Possible bacterial pathogens have been isolated and identified using standard laboratory techniques. MRSA was determined by means of the disc diffusion method to 5 micrograms of methicillin disc and 1 micrograms of oxacillin disc; an antimicrobial sensitivity test was performed by means of disc diffusion method of selected antibiotics. The ocular infections include conjunctivitis, keratitis, blepharitis and blepharo-conjunctivitis.

**Results:** Of a total of 197 cultured swabs, only 146 swabs produced a positive culture (74.1%). Gram-positive bacteria formed 52.1% of the total isolates where *S. aureus* was the predominant pathogen (30.1%). The prevalence of MRSA was 34.1%. There was a higher rate of antibiotic resistance tested in MRSA isolates compared to a lower rate of resistance in MSSA.

**Conclusion:** It can be concluded, *S. aureus* was the most common bacterial isolate in external ocular infections, high rate of MRSA, the emergence of *S. aureus* isolates resistant to wide range of antibiotics have raised MRSA in ocular infections into a multi-drug-resistant, making it more and more dangerous in ocular infections. Regular surveillance of ocular associated infections and monitoring antibiotic sensitivity pattern and strict drug policy for antibiotics are recommend.

**Keywords:** Antibiotic resistance, ocular infection, MRSA, *Staphylococcus aureus*, Sana'a, Yemen

**Abbreviations:** NCPHL: National Center of Public Laboratories ; MRSA: Methicillin-Resistant *S. aureus*; ESBL: Extended Spectrum Beta-Lactamase ; VRE: Vancomycin-Resistant Enterococcus; MRAB: Multidrug-Resistant *A. baumannii*

## Introduction

*Staphylococcus aureus* is one of the most important isolated bacterial human pathogens. The isolated Methicillin-resistant *S. aureus* (MRSA), which is usually resistant to other  $\beta$ -lactam-antimicrobial drugs, is called MRSA. MRSA, first identified in the 1960s, has traditionally been associated with health care facilities infections, but is now a dominant pathogen in community-related diseases [1]. MRSA is considered as a serious cause of morbidity and mortality worldwide with increasing prevalence, due to its multiple drug resistance, leaving limited treatment options. A series of MRSA catastrophic eye infections cases have been reported in patients after refractive surgery and cataracts surgeries [2-4]. According to the American Society of Cataract and Refractive Surgery report, MRSA bacteria replaced non-tuberculous mycobacteria as the most common pathogen causing infections after laser-assisted in situ keratomileusis [5]. MRSA has been reported to account for 18.2% (6/33) culture-confirmed endophthalmitis in a referral vitreo-retinal practice [3]. The proportion of MRSA in ocular *S. aureus* infections of a single institution varied from 3% to 30%, with some reports showing an increase in the incidence of MRSA to 41%. [6-8]. The surveillance network, which monitors patterns of sensitivity to antimicrobials for bacterial pathogens in the United States, reported an increase in the percentage of MRSA among *S. aureus* ocular infections in the USA, from 29.5% in 2000 to 71% in 2017, which showed that MRSA is an increased risk in the field of the eye [9-12].

In Yemen, the MRSA rate among *S. aureus* clinical isolates was range from 19.3% to 80% during 2015 to 2020 which is higher than the rate recorded in other regions of the world, [13-17] but the rate of eye infections due to MRSA is still unknown. Here, we performed this cross-sectional study to determine the rate of ocular MRSA infection and to determine the sensitivity of antibiotics to MRSA ocular infection by comparing those of ocular methicillin sensitive *S. aureus* (MSSA) infections.

## Patients, Materials and Methods

The study was conducted for a year, starting in September 2016 to October 2017, where a total of 197 patients with

external eye infections were included in the study. Samples were collected and transferred to the National Center of Public Laboratories (NCPHL), in Sana'a. Possible bacterial pathogens have been isolated and identified using standard laboratory techniques.

**Data collection and processing:** A questionnaire was filled out for each patient with the patient's personal and clinical data. This included age, gender, profession and relevant clinical information regarding bacterial and fungal ocular infections.

**Antimicrobial susceptibility test:** Antibiotic resistance phenotypes (Methicillin / Oxacillin sensitivity test): All isolates of *S. aureus* were tested for the susceptibility to 5  $\mu$ g Methicillin disc and 1  $\mu$ g Oxacillin disc provided by Difco using the disk diffusion method as described by NCCLS. The resistance breakpoints were  $\geq 14$  mm to  $\leq 10$  mm for 5  $\mu$ g Methicillin, and  $\geq 12$  mm to  $\leq 10$  mm for 1  $\mu$ g Oxacillin. The ability of other antibiotic disc to inhibit MRSA or MSSA were estimated according to the guidelines provided by NCCLS using commercially available discs which include: Amikacin (AK, 30 $\mu$ g), ceftriaxone (CRO, 30 $\mu$ g), gentamicin (CN, 10 $\mu$ g) ciprofloxacin (CIP, 5 $\mu$ g), penicillin (P, 10U), tetracycline (TE, 30 $\mu$ g), erythromycin (E, 15 $\mu$ g), doxycycline (DO, 30 $\mu$ g), chloramphenicol (C, 30 $\mu$ g), trimethoprim-sulphamethoxazole (SXT, 1.25/23.75 $\mu$ g ), and vancomycin (VA, 30 $\mu$ g). The zone of inhibition produced by *S. aureus* against each antibiotic was measured and interpreted as resistant and susceptible according to standards of Clinical Laboratory and Standards Institute [18].

## Results

The positive culture rate was 74.1% (146 out of 197) and 25.9% of the specimens were negative (table 1).

Results	Frequency	
	No	%
Positive culture	146	74.1
Negative culture	51	25.9
Total	197	100

**Table 1:** Cultural results of the 197 patients with external bacterial ocular infections.

Seventy six (52.1%) were Gram positive bacteria, 70 (47.9%) were Gram negative bacteria. The most frequent microorganism isolated was *S. aureus* (44 isolates) (Table 2).

Bacterial isolates	Positive for bacterial growth	
	N=146	%
	No	
Gram positive bacteria	76	52.1
<i>S. aureus</i>	44	30.1
Beta-haemolytic streptococcus	9	6.2
<i>S. pneumonia</i>	11	7.5
CoNs	12	8.2
Gram negative bacteria	70	47.9
<i>H. influenzae</i>	13	8.9
<i>Pseudomonas aeruginosa</i>	39	26.7
<i>Moraxella lacunata</i>	5	3.4
<i>E.coli</i>	11	7.5
Proteus spp	2	1.4
Total n=197	146	74.1

Mixed infection cases were excluded.

**Table 2:** Distribution of bacterial isolates of external ocular infection  
The prevalence of MRSA was 34.1%. Table 3 shows

Antibiotics	MRSA		MSSA		Total	
	n=15 (34.1%)		n=29 (65.9%)		N=44 (100)	
	Sensitive	Resistant	Sensitive	Resistant	sensitive	Resistant
Amikacin (30 µg)	13(86.7)	2(23.3)	29(100)	0(0.0)	42(95.5)	2(4.5)
Ceftriaxone (30 µg)	8(53.3)	7(46.7)	22(75.9)	7(24.1)	30(68.2)	14(31.8)
Chloroamphenicol (30 µg)	7(46.7)	8(53.3)	16(55.2)	13(44.8)	23(52.3)	21(47.7)
Ciprofloxacin(30 µg)	13(86.7)	2(23.3)	29(100)	0(0.0)	42(95.5)	2(4.5)
Doxycycline (30 µg)	9(60)	6(40)	25(86.2)	4(13.8)	34(77.3)	10(22.7)
Erythromycin (15 µg)	6(40)	9(60)	20(70)	9(30)	26(59)	18(41)
Gentamycin (10 µg)	12(80)	3(20)	28(96.6)	1(3.4)	40(90.9)	4(9.1)
Penicillin (30 µg)	0(0.0)	15(100)	1(3.4)	28(96.6)	1(2.3)	43(97.7)
Tetracycline (30 µg)	10(66.7)	5(33.3)	20(70)	9(30)	30(68.2)	14(31.8)
Trimethoprim-sulphamethoxazole (1.25/23.75 µg)	8(53.3)	7(46.7)	24(82.8)	5(17.2)	32(72.7)	12(27.3)
Vancomycin (30 µg)	11(73.3)	4(26.7)	27(93.1)	2(6.9)	38(86.4)	6(23.6)

**Table 3:** The antibiotic sensitivity for 44 isolated MRSA and MSSA for tested antibiotics.

The susceptibility patterns of *S. aureus* isolates towards the different commonly used antibiotics. As demonstrated above, we found that resistance to methicillin was often accompanied by higher rates of co-resistance to other antimicrobial classes. MRSA was significantly more resistant than MSSA to Amikacin (23.3% vs 4.5%), ceftriaxone (46.7% vs 24.1%), gentamicin (20% vs 3.4%), erythromycin (60%

vs 30%), ciprofloxacin (23.3% vs 0.0%, and vancomycin (26.7% vs 6.9%).

## Discussion

*Staphylococcus aureus* are the predominant community-acquired pathogens and the main cause of hospital infection

[19,20]. In part, the global spread of *S. aureus* is due to its ability to colonize the respiratory system and other epithelial and mucous surfaces effectively in healthy individuals, which act as trigger for spreading infection [21,22]. In addition, the capacity of *S. aureus* to arise resistance to multiple antibiotic classes, increases the selection and expansion of epidemic antibiotic strains that can escalate in both society and hospitals, posing a serious public health threat [23]. Community-acquired methicillin-resistant *S. aureus* (CA-MRSA), which cause mainly skin and soft tissue infections, have rapidly spread throughout the world following the first reported cases in the early sixties [1,8,9,24].

MRSA has also become a principal cause of clinically relevant eye infections [1-8], [25-27], which develops mainly in patients within the community and can lead to severe vision loss and poor outcomes for patients [28]. Staphylococcus aureus infection, including MRSA strains, has not been well studied in Yemen. The current study represents the first study of *S. aureus* infection in ocular infections and the prevalence of MRSA among ocular *S. aureus* in Yemen. The present rate of 34.1% of MRSA in all isolates of *S. aureus* is lesser than the rate reported from Yemen in previous reports in which MRSA was isolated from 55% of health workers in Taiz, Yemen [13], and is also lower than that reported by al-Baidani and others [14] among health care workers in Al-Hodeidah, where MRSA was 86%. On the other hand, it was slightly higher than that reported by Al-Safani and others [15] (19.3%) among patients attending the military hospital in the city of Sana'a; and Alyahawi, and others among patients of some private hospitals in the city of Sana'a (17.6%) [16]. Our MRSA rate (34.1%) is lower than reported from Taiwan, where MRSA accounted for 53% to 83% of all *S. aureus* clinical isolates [29], and in the USA where MRSA accounted for 71% of isolated clinical eye infection [9]. Therefore, these data indicate that MRSA is low prevalence and with a stable percentage of MRSA infection in Yemen where other clinical studies also have indicated a low MRSA rate such as Alsafani, et al. (19%) [15], and Al-Akwa'a, et al. (23%) [17]. Researchers in different parts of the world have shown an increase in the occurrence of ocular MRSA, for example in the United States of America rates increase from 12% to 33% over 5 years (2000 to 2004) [7], as another researcher reported a similar increase in the rate of infections MRSA in kind from 4.1% in 1998 -1999 to 16.7% in 2005-2006 to 71% in 2019 [8,9]. These results expect that MRSA could be more common than MSSA within the last feature, based on the rate of increase [30].

Although the rates of resistance to methicillin in our population were lower than that seen among hospitalized patients elsewhere [15,7-9], approximately one third of our *S. aureus* isolates (34.1%) were resistant to this important antibiotic. Additionally, as described above, we found

that resistance to methicillin was often accompanied by higher rates of co-resistance to other antimicrobial classes; where MRSA was significantly more resistant than MSSA to amikacin (23.3% vs. 4.5%), ceftriaxone (46.7% vs. 24.1%), gentamicin (20% vs. 3.4%), erythromycin (60% vs. 30%), ciprofloxacin (23.3% vs. 0.0%) and vancomycin (26.7% vs. 6.9%) although most other studies reported increased MRSA resistance strains to others antibiotics [7-9]. In the current study the resistant rate of MRSA to vancomycin was 26.7% higher than that of MSSA 6.9%, and this shows that vancomycin in MRSA is less effective. Previous studies support this finding [7,8,25]. Although vancomycin maintains extremely high efficacy against MRSA, *S. aureus* with reduced susceptibility to vancomycin was identified [30]. Because prior vancomycin use is a risk factor for MRSA with decreased vancomycin susceptibility, [31] and no realistic evidence shows that routine vancomycin prophylaxis is effective in elective cataract surgery [32,33], it is recommended that ophthalmologists should follow guidelines of the Centers for Disease Control and Prevention [34] and the American Academy of Ophthalmology [35] against the routine use of vancomycin for prophylaxis to stop the spread of resistance.

The current study and other previous studies show that there is a risk of antimicrobial resistance, so there is a need to increase public calls for global collective action to tackle the threat, including proposing an international treaty on antimicrobial resistance. More details and attention are still needed in order to identify and measure resistance trends at the national and international levels; The idea of a global tracking system was suggested but implementation has yet to happen. A system of this type will offer insight into areas with high resistance as well as information needed to evaluate programs and other changes that have been made to fight or reverse antibiotic resistance. Yemen should also participate in several national and international monitoring programs for drug-resistant threats, including [36-38].

## Conclusion

Prevalence of *S. aureus* in external ocular patients is quite high and showed resistance to commonly used antibiotics as well as carried moderate rate of MRSA. Despite these results, the sample size of this study is not sufficient and study period was too short to uncover actual picture of MRSA involved in ocular infection in Sana'a city, Yemen. Large scale studies could be done both in hospitalized patients and in community to identify prevalence of MRSA, genome analysis, identification of toxin gene and other antibiotic resistant gene.

## Acknowledgments

The authors would like to acknowledge Ministry of Health

and Population, Sana'a, Yemen and the National Center of Public Health Laboratories (NCPHL), Ministry of Health and Population, Sana'a, Yemen for their support and provided working space and materials.

### Author's Contribution

This research work is part of the National Center for Public Health Laboratories (NCPHL) and MSc project. The first author did clinical work and the second and third authors did the lab. The corresponding author (HAA) supervised laboratory works, reviewing and editing the research.

### Conflict of Interest

"There is no conflict of interest related to this work."

### References

1. Stan Deresinski (2005) Methicillin-resistant *Staphylococcus aureus*: an evolutionary, epidemiologic, and therapeutic odyssey. *Clin Infect Dis* 40(4): 562-573.
2. Renée Solomon, Eric D Donnenfeld, Henry D Perry, Roy S Rubinfeld, Michael Ehrenhaus, et al. (2007) Methicillin-resistant *Staphylococcus aureus* infectious keratitis following refractive surgery. *Am J Ophthalmol* 143(4): 629-634.
3. Vincent A Deramo, James C Lai, Jules Winokur, Jodi Luchs, Ira J Udell, et al. (2008) Visual outcome and bacterial sensitivity after methicillin-resistant *Staphylococcus aureus*-associated acute endophthalmitis. *Am J Ophthalmol* 145(3): 413-417.
4. James C Major Jr, Michael Engelbert, Harry W Flynn Jr, Darlene Miller, William E Smiddy, et al. (2010) *Staphylococcus aureus* endophthalmitis: antibiotic susceptibilities, methicillin resistance, and clinical outcomes. *Am J Ophthalmol* 149(2): 278-283.e1.
5. Renée Solomon, Eric D Donnenfeld, Edward J Holland, Sonia H Yoo, Sheraz Daya, et al. (2011) Microbial keratitis trends following refractive surgery: results of the ASCRS infectious keratitis survey and comparisons with prior ASCRS surveys of infectious keratitis following keratorefractive procedures. *J Cataract Refract Surg* 37(7): 1343-1350.
6. Shanmuganathan VA, Armstrong M, Buller A, Tullo AB (2005) External ocular infections due to methicillin-resistant *Staphylococcus aureus* (MRSA). *Eye(Lond)* 19(3): 284-291.
7. Preston Howard Blomquist (2006) Methicillin-resistant *Staphylococcus aureus* infections of the eye and orbit (an American Ophthalmological Society thesis). *Trans Am Ophthalmol Soc* 104: 322-345.
8. Julie Freidlin, Nisha Acharya, Thomas M Lietman, Vicky Cevallos, John P Whitcher, et al. (2007) Spectrum of eye disease caused by methicillin-resistant *Staphylococcus aureus*. *Am J Ophthalmol* 144(2): 313-315.
9. Peterson JC, Durkee H, Miller D, Maestre-Mesa J, Arboleda A, et al. (2019). Molecular epidemiology and resistance profiles among healthcare- and community-associated *Staphylococcus aureus* keratitis isolates. *Infection and Drug Resistance* 12: 831-843.
10. Emily S Wong, Claire W Y Chow, Luk WK, Kitty S C Fung, Kenneth K W Li (2017) A 10-year review of ocular methicillin-resistant *Staphylococcus aureus* infections: epidemiology, clinical features, and treatment. *Cornea* 36(1): 92-97.
11. Penny A Asbell, Kathryn A Colby, Sophie Deng, Peter McDonnell, David M Meisler, et al. (2008) Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. *Am J Ophthalmol* 145(6): 951-958.
12. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, et al. (2001) Survey of infections due to *Staphylococcus* species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. *Clin Infect Dis* 32(2): S114-132.
13. Abdel Monem, MO (2012) Nasal Carriage of *Staphylococcus aureus* among Healthcare Workers in Althawra Hospital, Taiz City, Republic of Yemen. *Australian Journal of Basic and Applied Sciences* 6(7): 417-424.
14. Al-Baidani AR, El-Shouny WA and Shawa TM (2011) Antibiotic susceptibility of MRSA in three hospitals at Hodeida city Yemen. *Globe J Pharma* 5(2): 106-111.
15. Ahmed Mohammed Ali Al-Safani, Hassan A. Al-Shamahy, Khaled A. Al-Moyed (2018) Prevalence, antimicrobial susceptibility pattern and risk factors of MRSA isolated from clinical specimens among military patients at 48 medical compound in Sana'a city-Yemen. *Universal Journal of Pharmaceutical Research* 3(3): 40-44.
16. Ali Alyahawi, Ali Alkaf, Abdul Monem Alhomidi (2018) Prevalence of methicillin resistant *staphylococcus aureus* (MRSA) and antimicrobial susceptibility patterns at a private hospital in Sana'a, Yemen. *Universal Journal of Pharmaceutical Research* 3(3): 4-9.

17. Ameen Abdullah Yahya Al-Akwa, Abdul Qader Mohammed Qasem Zabara, Hassan Abdulwahab Al-Shamahy, Mohammed A Al-labani, Khaled M Al-Ghaffari, et al. (2020) Prevalence of Staphylococcus aureus in dental infections and the occurrence of MRSA in isolates. *Universal Journal of Pharmaceutical Research* 5(2): 23-27.
18. Clinical and Laboratory Standards Institute [CLSI] (2012). Performance Standards for Antimicrobial Disc Susceptibility Tests. 11<sup>th</sup> (Edn.), Approved standard M02-A11- Publication of Clinical and Laboratory Standards Institute [CLSI], 2012; USA, 32.
19. Helen W Boucher, G Ralph Corey (2008) Epidemiology of Methicillin-Resistant Staphylococcus aureus. *Clin Infect Dis* 46(5): S344-S349.
20. Michael Z David, Robert S Daum (2010) Community-Associated Methicillin-Resistant Staphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging Epidemic. *Clinical Microbiology Reviews* 23(3): 616-687.
21. Pak-Leung Ho, Susan S Chiu, Maggie Y Chan, Yuki Gan, Kin-Hung Chow, et al. (2012) Molecular Epidemiology and nasal carriage of Staphylococcus aureus and methicillin-resistant *S. aureus* among young children attending day care centers and kindergartens in Hong Kong. *J Infect* 64(5): 500-506.
22. Heiman F L Wertheim, Damian C Melles, Margreet C Vos, Willem van Leeuwen, Alex van Belkum, et al. (2005) The role of nasal carriage in Staphylococcus aureus infections. *Lancet Infect Dis* 5(12): 751-762.
23. CDC CfDCaP- (2013). Antibiotic Resistance Threats in the United States.
24. Centers for Disease Control and Prevention (1999). Four Pediatric Deaths from Community-Acquired Methicillin-Resistant Staphylococcus aureus—Minnesota and North Dakota. *JAMA* 282(12): 1123-1125.
25. Penny A Asbell, Daniel F Sahm, Mary Shaw, Deborah C Draghi, Nina P Brown (2008) Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005. *J Cataract Refract Surg* 34(5): 814-818.
26. Kara Cavuoto, Deepti Zutshi, Carol L Karp, Darlene Miller, William Feuer (2008). Update on bacterial conjunctivitis in South Florida. *Ophthalmology* 115(1): 51-56.
27. Ali Qureishi, Yan Lee, Katherine Belfield, John P Birchall, Matija Daniel (2014) Update on otitis media—prevention and treatment. *Infect Drug Resist* 10(7): 15-24.
28. Ama Sadaka, Marlene L Durand, Robert Sisk, Michael S Gilmore (2017) Staphylococcus aureus and its bearing on ophthalmic disease. *Ocul Immunol Inflamm* 25(1): 111-121.
29. Hsueh PR, Liu CY, Luh KT (2002) Current status of antimicrobial resistance in Taiwan. *Emerg Infect Dis* 8: 132-137.
30. Stephen P Hawser, Samuel K Bouchillon, Daryl J Hoban, Michael Dowzicky, Tim Babinchak (2011) Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004–2009. *Int J Antimicrob Agents* 37(3): 219–224.
31. Scott K Fridkin, Jeff Hageman, Linda K McDougal, Jasmine Mohammed, William R Jarvis, et al. (2003) Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997–2001. *Clin Infect Dis* 36(4): 429–439.
32. Gordon YJ (2001) Vancomycin prophylaxis and emerging resistance: are ophthalmologists the villains? The heroes? *Am J Ophthalmol* 131(3): 371–376.
33. Endophthalmitis Study Group; European Society of Cataract; Refractive Surgeons (2007). “Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors”. *J Cataract Refract Surg* 33 (6): 978–988.
34. CDC (1995) CDC issues recommendations for preventing spread of vancomycin resistance. *Am J Health Syst Pharm* 52(12): 1272–1274.
35. Force A-CT (1999) The prophylactic use of vancomycin for intraocular surgery. *Quality of Care Publications*, Number 515, American Academy of Ophthalmology, San Francisco, CA, October
36. CDC (2018). “Biggest Threats – Antibiotic/Antimicrobial Resistance – CDC”. [www.cdc.gov](http://www.cdc.gov). 10 September 2018.
37. O’Callaghan RJ (2018) The pathogenesis of Staphylococcus aureus eye infections. *Pathogens* 7(1): 9.
38. Anne-Catrin Uhlemann, Michael Otto, Franklin D Lowy, Frank R DeLeo (2014) Evolution of community-and healthcare-associated methicillin-resistant Staphylococcus aureus. *Infect Genet Evol*; 21:563–574.